Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) disclosed that it repurchased 560,000 H-shares on 15 June 2026 via on-market transactions on the Hong Kong Stock Exchange. The shares were bought at prices ranging between HKD 3.28 and HKD 3.38, resulting in an average cost of HKD 3.3114 per share and an aggregate consideration of HKD 1.85 million.
Following the transaction, Weigao Group’s issued share capital (excluding treasury shares) decreased by 0.01 % to 4.464 billion shares, while the company’s treasury stock rose to 58.63 million shares. The total number of issued shares remained unchanged at 4.522 billion.
The repurchased shares will be held as treasury shares; no cancellations have been executed to date. The buyback forms part of the mandate approved by shareholders on 29 May 2026, which authorises the company to repurchase up to 446.46 million shares. Cumulative buybacks under this mandate now stand at 1.30 million shares, representing 0.29 % of the shares outstanding at the mandate date.
In line with Hong Kong listing regulations, Weigao Group is subject to a moratorium on issuing new shares or disposing of treasury shares until 15 July 2026. The company confirmed that the repurchase complied with all applicable laws, listing rules and board authorisations.
Comments